In co-localisation analysis, however, there was little evidence that genetic liability to type 2 diabetes and these cancer endpoints shared one or more causal variants within PPARG, though these analyses were likely underpowered given low posterior probabilities to support both H3 (i.e. distinct causal variants) and H4 (i.e. shared causal variants) across these analyses. This evidence concerns the gene PPARG and type 2 diabetes mellitus.